Biosimilars, drug shortages are on the Belgian antitrust radar
The Belgian competition authority will focus on pharma companies in cases where their practices might hamper the availability of essential medicines for Belgian patients, as well as when they might unlawfully...To view the full article, register now.
Already a subscriber? Click here to view full article